Internal and Emergency Medicine

, Volume 13, Issue 7, pp 1005–1007 | Cite as

The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey

  • Giuseppe Mulè’Email author
  • Caterina Carollo
  • Marco Guarneri
  • Santina Cottone

Atrial fibrillation is the most common sustained cardiac dysrhythmia. It represents a major public health problem due to increased mortality risk, reduced quality of life, and increased health costs [1, 2].

The prevalence of nonvalvular atrial fibrillation (AF) continues to increase worldwide, largely affecting the elderly, but also occurring in younger patients as a result of structural heart disease, autonomic imbalance, genetic abnormality, or previous cardiac surgery [3]. The rise in prevalence of AF is largely due to the increasing age of the population. About 1–2% of the total population is affected by AF, but the prevalence of this condition rises to ≈ 10% in individuals aged > 75 years [1, 2, 3]. In Europe, the number of adults with AF is rising markedly, with 9 million affected individuals in 2010, and 17 million expected patients in 2050, with an alarming impact on morbidity and mortality [4]. The associated fivefold risk of stroke is one of the most feared complications of...



The authors report no specific funding in relation to the preparation of this paper.

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animal performed by any of the authors.

Informed consent

No informed consent is required.


  1. 1.
    Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609–1678CrossRefPubMedGoogle Scholar
  2. 2.
    January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:2245–2280. CrossRefGoogle Scholar
  3. 3.
    Chugh SS, Roth GA, Gillum RF, Mensah GA (2014) Global burden of atrial fibrillation in developed and developing nations. Glob Heart 9:113–119. CrossRefPubMedGoogle Scholar
  4. 4.
    Krijthe BP, Kunst A, Benjamin EJ et al (2013) Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34:2746–2751. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Healey JS, Alings M, Ha A et al (2017) Subclinical atrial fibrillation in older patients. Circulation 136:1276–1283. CrossRefPubMedGoogle Scholar
  6. 6.
    Ferro D, Loffredo L, Polimeni L, Violi F (2007) Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2:24–28. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ogilvie IM, Newton N, Welner SA et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123:638.e4–645.e4. CrossRefGoogle Scholar
  8. 8.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891. CrossRefPubMedGoogle Scholar
  9. 9.
    Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962. CrossRefPubMedGoogle Scholar
  10. 10.
    Larsen TB, Skjøth F, Nielsen PB et al (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Prisco D, Ageno W, Becattini C et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12:387–406. CrossRefPubMedGoogle Scholar
  12. 12.
    Borghi C, Paolillo S, Cicero AFG et al (2017) New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation. J Hypertens 35:689–695. CrossRefPubMedGoogle Scholar
  13. 13.
    Hsu JC, Maddox TM, Kennedy KF et al (2016) Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk. JAMA Cardiol 1:55. CrossRefPubMedGoogle Scholar
  14. 14.
    Kjerpeseth LJ, Ellekjær H, Selmer R et al (2017) Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 73:1417–1425. CrossRefPubMedGoogle Scholar
  15. 15.
    Gülker J-E, Kröger K, Kowall B et al (2018) Increasing use of anticoagulants in Germany and its impact on hospitalization for intracranial bleeding. Circ Cardiovasc Qual Outcomes 11:e004470. CrossRefPubMedGoogle Scholar
  16. 16.
    Volterrani M, Iellamo F, Alberto C et al (2018) NOAC in “real world” patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. 2 Intern Emerg Med. (in press) CrossRefPubMedGoogle Scholar
  17. 17.
    Huisman MV, Rothman KJ, Paquette M et al (2017) The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69:777–785. CrossRefPubMedGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  1. 1.Unit of Nephrology and Hypertension - Biomedical Department of Internal Medicine and Medical Specialties (Di.Bi.M.I.S) - European Society of Hypertension Excellence CentreUniversity of PalermoPalermoItaly

Personalised recommendations